抗膀胱癌单克隆抗体导向的粘附性LAK细胞体外抗膀胱癌作用的研究

An in vitro study on the specific killing effect of anti-bladder cancer monoclonal antibody-directed A-LAK cells against bladder cancer

为了进一步探索治疗膀胱癌的新途径，用人体脾脏组织制备粘附性淋巴因子激活的杀伤细胞（Ａ－ＬＡＫ细胞），通过生物素－亲和素系统将抗人膀胱癌单克隆抗体（ＢＤＩ－１）与Ａ－ＬＡＫ细胞偶联构建出ＢＤＩ－１－Ａ－ＬＡＫ细胞偶联物。采用４小时５１Ｃｒ释放法测定ＢＤＩ－１－Ａ－ＬＡＫ细胞偶联物体外对人膀胱癌ＢＩＵ－８７细胞的杀伤率，结果显示，扩增５天从每克人脾脏组织可制备得５．５×１０８个Ａ－ＬＡＫ细胞，ＢＤＩ－１－Ａ－ＬＡＫ细胞偶联物对ＢＩＵ－８７细胞具有较强的特异性杀伤作用。

Adherent lymphokine-activated killer(A-LAK)cells were generated from human spleen tissue. Anti-bladder cancer monoclonal antibody(BDI-1)and A-LAK cells were conjugated by virtue of biotin-avidin system to form BDI-1-conjugated A-LAK cells. Cytotoxicity of BDI-1-conjugated A-LAK cells against BIU-87 human bladder cancer cells in vitro was determined by 4h 51Cr release assay. The results showed around 5.5×108 A-LAK cells could be generated from per milligram spleen tissue and BDI-1-conjugated A-LAK cells had strong specific killing effect against BIU-87 cells. BDI-1-conjugated A-LAK cells were therefore expected to be used in the targeting immunotherapy of bladder cancer.